Catalya raises €1.5M to make medicine easier to swallow
What's the deal? CatalyaDealroom has a profile for this one. Try Dealroom →, a spin-off of the University of Liège, has raised €1.5 million in an early-stage round to advance its research into easier drug administration.
Founded in 2019, the Belgian startup is developing a solution to simplify how certain medicines are taken.
If its research succeeds, it could reshape how patients receive treatment.
Why now? The funding comes as drug developers face growing pressure to improve patient compliance, where hard-to-swallow or poorly tolerated medicines often limit treatment outcomes.
For Catalya, the round provides capital to push its university research towards a viable commercial product.
What could go wrong? The startup's promise hinges on research that has yet to be proven at scale.
Early-stage pharma ventures face long development timelines and tight regulatory scrutiny, and there is no guarantee the technology reaches the market.
The signal: Catalya's polymer platform spans both drug delivery and cell culture, suggesting the University of Liège spin-off is positioning its technology across multiple healthcare applications rather than a single product. As an early-stage venture, this €1.5 million round buys time to prove that breadth before committing to a commercial focus.
Read more: L'Echo
Image credit: Generated with Gemini
